LELYSTAD, Netherlands, December 13 /PRNewswire/ -- Pespcan systems announced today that it has appointed Kenneth freeman, MBA, MPA, Ph.D. as chief financial officer. Prior to joining Pepscan, Dr. Freeman was a co-founder and Vice Chairman of the Supervisory Board of NADAG, (Munich), was Senior Director, Financial Operations, and Board Member ThromboGenics Ltd. (Dublin), and was a Consultant at UCL Biomedica(London) . In addition he has served as a consultant to several UK and European early stage and university spinout life sciences company’s. Dr. Freeman was a Senior Analyst at the US Congressional Office of Technology Assessment and a Visiting Scholar at MIT. He has been active in researching and promoting entrepreneurship in Europe, including designing and leading Business Plan workshops at Flanders Business School and as a consultant to EFER and INDIVERS Research . He has been a Research Fellow at INSEAD, and a Case Writer at London Business School, and served as a Board Member of the Irish Biotech Industry Association. He has an MBA and a MPA from Harvard, and a PhD. From King’s College, London.
Joost van Bree, Ph.D., CEO of Pepscan commented. “Pepscan is fortunate to be able to strengthen its management team with a CFO with a proven track record in both North America and Europe. This will help ensure Pepscan is able to remain a leader in the development of therapeutic cancer vaccines and associated technologies.
About Pepscan
Pepscan Systems BV is a product-oriented drug discovery and development company that focuses on innovative peptide-based therapeutic vaccines in oncology.
Pepscan Systems BV has proprietary technologies (CLIPS(TM), Chemically LInked Peptides on Scaffolds) for identification and functional reconstruction of complex protein domains. CLIPS(TM) technology makes it possible to identify effective vaccines and antibodies against `difficult` target (e.g GPCRs).
Pepscan applies these technologies in a strong internal pipeline and in risk-sharing collaborations.
Website: www.pepscan.com
